ASCO 2019 Nierenzellkarzinom: Sämtliche Subgruppen profitieren von Pembrolizumab/Axitinib
OA Dr. Franz Stoiber, Abteilung für Urologie und Andrologie, Salzkammergut-Klinikum Vöcklabruck, berichtet über ein Update der Keynote-426-Studie mit Pembrolizumab/Axitinib beim metastasierten Nierenzellkarzinom (mRCC) und erklärt, wem eine verzögerte Nephrektomie nützt.
Abstracts, die im Video diskutiert werden
Abstract 4500
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Brian I. Rini
Abstract 4502
Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
Leonard Joseph Appleman
Abstract 4508
Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.
Arnaud Mejean
Poster Icon Poster Board: #342 • Abstract 4516
Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).
Igal Kushnir